Collaboration and License Agreement - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jul. 01, 2021	Jan. 01, 2021	Dec. 31, 2020	Jul. 01, 2020	Jan. 01, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement revenue recognized	$ 1,677,000	$ 567,000	$ 33,169,000	$ 1,722,000
Novartis
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration Revenue			26,900,000
Novartis | Collaborative Arrangement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement revenue recognized	900,000	$ 600,000	30,800,000	$ 1,700,000
Deferred revenue	0		0		$ 800,000	$ 30,200,000	$ 30,200,000	$ 200,000	$ 600,000
Novartis | Collaborative Arrangement | Reimbursable Research and Development Costs
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts receivable	$ 100,000		$ 100,000				$ 400,000